Jaguar Health, INC 8-K filings

Jaguar Health has extended its agreement with Lucid Capital Markets to continue as a manager for its at-the-market offering until November 30, 2024.

Jaguar Health announced a 14% increase in Q3 2024 revenue compared to Q2 2024, driven by growth in prescription and non-prescription product sales, and provided updates on its clinical programs.

Jaguar Health announced a 16% increase in Q2 2024 revenue compared to Q1 2024, driven by prescription and non-prescription product sales, and is planning an October 2024 launch for Gelclair.

Jaguar Health's Phase 3 OnTarget trial for crofelemer did not meet its primary endpoint across all tumor types, but showed clinically relevant signals in breast and respiratory cancer subgroups.

Jaguar Health has amended its At-the-Market Offering Agreement to include Lucid Capital Markets as a manager alongside Ladenburg Thalmann, effective until September 30, 2024, unless extended.

Jaguar Health, Inc. issued 455,000 shares of common stock to reduce its royalty debt by $1,851,850.

Jaguar Health has regained compliance with Nasdaq's minimum bid price requirement and is set to report pivotal phase 3 trial results for its cancer supportive care drug, crofelemer, by July 23, 2024.

Jaguar Health successfully passed all five proposals at its 2024 Annual Meeting of Stockholders and anticipates reporting pivotal phase 3 trial results for its cancer supportive care drug crofelemer by July 23, 2024.

Jaguar Health, Inc. issued 393,700 shares of common stock to reduce its royalty debt by $1.5 million.

Jaguar Health has enacted a 1-for-60 reverse stock split and amended its at-the-market offering agreement, removing the previous $75 million limit.

Jaguar Health has announced the successful approval of all proposals at its special shareholder meeting, including the authorization for a reverse stock split, while also receiving an extension to regain Nasdaq compliance.

Jaguar Health has entered into a licensing agreement with Gen Ilac for its drug Crofelemer in Eastern Europe, including a $2 million investment in Jaguar stock at a 75% premium.

Jaguar Health, Inc. issued 10 million common shares in exchange for 40 shares of Series J Preferred Stock in a privately negotiated agreement with Streeterville Capital, LLC.

Jaguar Health, Inc. finalized agreements to extinguish a royalty interest and exchange outstanding warrants for common stock, issuing new preferred and common shares in the process.

Jaguar Health, Inc. has received a delisting notice from Nasdaq after its stock price remained below $0.10 for ten consecutive trading days.